| Drug/Treatment | MOA | Status | Conditions |
| Aduhelm (aducanumab) | A monoclonal antibody that targets beta-amyloid plaques in the brain | Approved in June 2021 | Mild cognitive impairment due to AD or mild AD |
| Gantenerumab | A monoclonal antibody that targets beta-amyloid plaques in the brain. | Phase III clinical trials | Mild AD |
| Donanemab | A monoclonal antibody that targets a modified form of beta-amyloid called N3pG | Phase III clinical trials | Early AD |
| Tauvid Imaging (flortaucipir F18) | A diagnostic imaging agent that targets tau protein | Approved on May 2020 | Detection of tau pathology in the brain |
| Leqembi (Lecanemab) | Remove sticky clumps of the toxic protein amyloid-β from the brain. | Approved on 6 January 2023 | Alzheimer’s disease |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.